(Reuters) -Shares of Sarepta sank 36% before the bell on Tuesday after a trial for two gene-targeted therapies for a ...
6don MSN
Sarepta’s stock plummets as disappointing trial data raise questions on DMD drug’s success
Sarepta’s stock plunged about 38% in after-hours trading, after it closed the regular session up 1.8%. That decline would put ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback